Paradromics announced on 17 June 2026 that University of Michigan surgeons have implanted its Connexus brain-computer interface in a woman with motor neuron disease, the first patient in the FDA-approved Connect-One early feasibility study. She will be followed for six years.
WISE S.p.A., an Italian implantable-electrode company working in neuromonitoring, neuromodulation and BCI, closed an oversubscribed €30 million ($34.8M) Series D on 17 June 2026. The lead application is the company's Heron percutaneous spinal cord stimulation lead.
Per China Daily, the city of Tianjin formally inaugurated a dedicated BCI industrial cluster at the 2026 World Intelligence Expo, with 100 million yuan (about $14.8M) annual funding committed, 22 BCI companies already incubated in the zone, and a target of 50 enterprises by 2027.
Casey Harrell, who has ALS, used a UC Davis intracortical speech BCI at home for more than 3,800 hours over 22 months without researchers present. Nature Medicine published the case on 15 June 2026.
Yale's Nature Neuroscience study reports that healthy participants learned to control a video game avatar in under an hour when the fMRI decoder followed each user's individual neural manifold. Off-manifold mappings produced no learning at all.
In June 2026 Bezos's capital crossed into brain-inspired AI (Flourish, close to $100M at $2.5B) and basic neuroscience (Allen Institute family gift, $100M). With Bezos Expeditions in Synchron, no other tech billionaire spans this many neurotech layers.
Flourish, a New York neuro-AI startup founded in 2024 by Thomas Reardon (Internet Explorer architect at Microsoft in 1994 and CTRL-labs co-founder who sold the company to Meta in 2019 for between $500 million and $1 billion) and former Amazon S-team executive Rob Williams, closed a $500 million round at a $2.5 billion valuation around 4 June 2026. Jeff Bezos contributed close to $100 million after nearly doubling an initial $50 million commitment. Other investors include Lux Capital, GV (Alphabet), and Catalio Capital. The company is building Cortex AI, an architecture-layer system that uses connectomics, the cell-by-cell mapping of biological neural connections, to design AI models that target 20-50 watts of energy draw, roughly the power consumption of a laptop and an order of magnitude lower than a server-grade GPU. Flourish has no product yet.
Neuronoff announced on 5 June 2026 that it has implanted the first patient in a US Department of Defense-funded clinical trial of its Injectrode, a helical platinum-iridium peripheral nerve electrode delivered through a single 18-gauge needle under local anaesthesia, in patients with neurogenic bladder dysfunction following spinal cord injury. The trial (NCT07264868) is being run at UT Health Houston under principal investigator Dr Argyrios Stampas, Associate Professor and Vice Chair of Research and Innovation in the Department of Physical Medicine and Rehabilitation at McGovern Medical School. It is a Phase 1/2 randomised controlled study enrolling 21 participants across three arms (unilateral active stimulation, bilateral active stimulation, sham), with primary endpoints at 4 and 8 weeks assessing safety, stimulation accuracy, procedural feasibility, and physician and patient acceptability. This is the first-in-human spinal cord injury trial of the Injectrode.
The Allen Institute announced on 2 June 2026 a $400 million global research initiative called the Brain Health accelerator, targeting neurodegenerative disease at the cell and circuit level. Capital is $200 million from the Allen Institute, $100 million from the Bezos family (whose Bezos Expeditions arm backs Synchron), and $100 million combined from AWS, NIH, and ALS advocacy organisation EverythingALS. The ALS focus is the most direct adjacency to the implantable BCI cohort, which has anchored most of its early commercial work on ALS patients.
Get the latest BCI news, breakthroughs, and market moves delivered to your inbox.
No spam. One-click unsubscribe. We respect your privacy.